Patent: 6,355,245
✉ Email this page to a colleague
Summary for Patent: 6,355,245
Title: | C5-specific antibodies for the treatment of inflammatory diseases |
Abstract: | The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system. |
Inventor(s): | Evans; Mark J. (Cheshire, CT), Matis; Louis A. (Southport, CT), Mueller; Eileen Elliott (East Haven, CT), Nye; Steven H. (Mequon, WI), Rollins; Scott (Monroe, CT), Rother; Russell P. (Cheshire, CT), Springhorn; Jeremy P. (Cheshire, CT), Squinto; Stephen P. (Bethany, CT), Thomas; Thomas C. (Madison, CT), Wilkins; James A. (Woodbridge, CT) |
Assignee: | Alexion Pharmaceuticals, Inc. (Cheshire, CT) |
Application Number: | 08/487,283 |
Patent Claims: | see list of patent claims |
Details for Patent 6,355,245
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Alexion Pharmaceuticals, Inc. | SOLIRIS | eculizumab | Injection | 125166 | March 16, 2007 | ⤷ Sign Up | 2019-03-12 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,355,245
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9529697 | ⤷ Sign Up |
United States of America | 6074642 | ⤷ Sign Up |
Portugal | 758904 | ⤷ Sign Up |
Netherlands | 300433 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |